GPN Vaccines

About

GPN Vaccines develops Gamma-PN, a broad-spectrum pneumococcal vaccine candidate, currently in first-in-human trials in Australia evaluating serotype-independent opsonophagocytic antibody responses.

Mission

GPN Vaccines is developing a vaccine against one of the world’s most prolific bacterial pathogens, responsible for a wide range of illnesses including middle ear infections and severe pneumonia. The company is described as an Australian start-up. In its latest financing the business secured capital that has produced a reported $300 million valuation. The round raised US$12 million (reported as A$18 million). The financing was led by New York‑based Forepont Capital, San Francisco’s Kern Capital and Mike Gregg, founding partner of local fund Shearwater Capital. The article does not report revenue, users, founding year, or additional operational metrics. GPN Vaccines is developing Gamma-PN (also referred to as Gamma-PNTM), a candidate broad-spectrum pneumococcal vaccine intended to protect against all S. pneumoniae serotypes. The company has commenced a first-in-human clinical trial in 50–69-year-old volunteers in Australia to evaluate the vaccine's ability to elicit protective, serotype-independent opsonophagocytic antibody responses. Management says the program aims to offer protection against serotypes not covered by existing vaccines and that preclinical data were published in mBio. Financially, the company strengthened its balance sheet with the recently closed Series A3 round and received a grant from the South Australian Government’s Research and Innovation Fund. GPN Vaccines is a public (unlisted) company and says the new funding extends its runway and resources to comprehensively test Gamma-PNTM in human trials. The team emphasizes the global importance of a vaccine that could protect against emerging pneumococcal serotypes.

Quick Facts